Imfinzi is the first immunotherapy to demonstrate significant overall survival benefit in unresectable, Stage III lung cancer

Pressemeddelelser   •   Sep 26, 2018 08:43 CEST

Imfinzi reduced the risk of death by nearly one third compared to standard of care in the Phase III PACIFIC trial Updated data reaffirm unprecedented improvement in progression-free survival of more than 11 months

European Commission approves Imfinzi for locally-advanced, unresectable NSCLC

Pressemeddelelser   •   Sep 26, 2018 08:28 CEST

Phase III PACIFIC trial demonstrated compelling overall survival benefit and progression-free survival of more than 11 months Imfinzi is the only immunotherapy medicine approved for the treatment of locally-advanced, unresectable NSCLC

Om AstraZeneca A/S

AstraZeneca er en af verdens førende medicinalvirksomheder inden for forskning, udvikling, fremstilling og markedsføring af receptpligtig medicin.

Adresse